| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.15 | 0.4 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.4 |